BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Cisplatin: trial readouts and FDA decisions
18 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 27 readout(s) in the last 180 days and 1 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, Merck Sharp & Dohme LLC, Innovent Biologics (Suzhou) Co. Ltd., CSPC Megalith Biopharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Qilu Pharmaceutical Co., Ltd., Karyopharm Therapeutics Inc, Boehringer Ingelheim, CSPC Megalith Biopharmaceutical Co., Ltd., Nanjing Leads Biolabs Co., Ltd, Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Akeso, RemeGen Co., Ltd., CStone Pharmaceuticals, Seagen, a wholly owned subsidiary of Pfizer, Bristol-Myers Squibb, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd, Taiho Oncology, Inc., Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Takeda, Bio-Thera Solutions, mAbxience Research S.L., Regeneron Pharmaceuticals, Hoffmann-La Roche, Jazz Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Avyxa Holdings, LLC, CSPC Megalith Biopharmaceutical Co., Ltd., Nanjing Leads Biolabs Co., Ltd, Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., RemeGen Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd, Taiho Oncology, Inc., Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd, TJ Biopharma Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Avyxa Holdings, LLC, CSPC Megalith Biopharmaceutical Co.,Ltd., Nanjing Leads Biolabs Co.,Ltd, Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., RemeGen Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Genelux Corporation, Shanghai Runshi Pharmaceutical Technology Co., Ltd, Taiho Oncology, Inc., Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co.,Ltd, TJ Biopharma Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Avyxa Holdings, LLC. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 990 |
| 2026-11-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | recruiting | 170 |
| 2026-11-30 est. | P2 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No | Non-Small Cell Lung Cancer | not yet recruiting | 120 |
| 2026-12 est. | P2/P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | active not recruiting | 501 |
| 2026-12-10 est. | P3 | Boehringer Ingelheim | NCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standar | Lung Cancer, Non-squamous, Non-small Cell | active not recruiting | 428 |
| 2026-12-28 est. | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | Advanced Neuroendocrine Carcinoma | recruiting | 178 |
| 2026-12-30 est. | P3 | Janssen Research & Development, LLC | NCT04658862 A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Urinary Bladder Neoplasms | active not recruiting | 518 |
| 2026-12-30 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer | Biliary Tract Cancer | active not recruiting | 93 |
| 2026-12-31 est. | P1/P2 | Akeso | NCT05229497 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | Advanced Malignant Tumors | active not recruiting | 154 |
| 2026-12-31 est. | P3 | RemeGen Co., Ltd. | NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | Urothelial Carcinoma; HER2-expressing | recruiting | 452 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EG | Metastatic Non-small Cell Lung Cancer | active not recruiting | 768 |
| 2027-01-29 est. | P3 | Seagen, a wholly owned subsidiary of Pfizer | NCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Urothelial Carcinoma | active not recruiting | 412 |
| 2027-01-31 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99 | Urinary Bladder Neoplasms | active not recruiting | 520 |
| 2027-02-05 est. | P2 | Bristol-Myers Squibb BMY | NCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Un | Non-Small Cell Lung Cancer | active not recruiting | 76 |
| 2026-12 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients Wi | Non-Small Cell Lung Cancer | active not recruiting | 432 |
| 2026-12 est. | P3 | Genelux Corporation GNLX | NCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primar | recruiting | 186 |
| 2027-02 est. | P2 | Genelux Corporation GNLX | NCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; M | recruiting | 142 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-06-17 | Complete response letter | approved since | Avyxa Holdings, LLC | Cisplatin | CRL 2026-06-17: Avyxa Holdings, LLC NDA 220748 (Cisplatin Injection) |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | Unresectable Locally Advanced or Metastatic Solid Tumors | not yet recruiting | 380 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherap | Carcinoma, Non-Small-Cell Lung | active not recruiting | 103 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma; Biliary Tract Cancer | active not recruiting | 294 |
| 2026-10-01 est. | P2 | Taiho Oncology, Inc. | NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Ade | active not recruiting | 53 |
| 2026-10 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer | CLDN18.2-positive Advanced Biliary Tract Cancer | not yet recruiting | 120 |
| 2026-10 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2026-10 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | 248 |
| 2026-09-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 506 |
| 2026-09-22 | P3 | Takeda TAK | NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | 354 |
| 2026-09 est. | P2/P3 | Bio-Thera Solutions | NCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Cervical Cancer | recruiting | 526 |
| 2026-08-31 est. | P3 | mAbxience Research S.L. | NCT06687369 A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer | active not recruiting | 726 |
| 2026-08-24 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in A | Resectable Non-small Cell Lung Cancer | active not recruiting | 195 |
| 2026-08 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | Non-small Cell Lung Cancer | recruiting | 110 |
| 2026-07-31 | P3 | Hoffmann-La Roche | NCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | completed | 11 |
| 2026-07-30 est. | P3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01) | EGFR-mutated Locally Advanced or Metastatic NSCLC | recruiting | 380 |
| 2026-07-15 | P3 | Jazz Pharmaceuticals JAZZ | NCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal | Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma | active not recruiting | 920 |
| 2026-07-10 | P3 | AstraZeneca AZN | NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tu | Non-small Cell Lung Cancer | active not recruiting | 25 |
| 2026-07-06 | P3 | AstraZeneca AZN | NCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treat | Carcinoma; Non-Small-Cell Lung | active not recruiting | 341 |
| 2026-07 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06372626 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | Neuroendocrine Carcinoma | unknown | 93 |
| 2026-06-30 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | Advanced Solid Tumor | not yet recruiting | 360 |
| 2026-06-15 | P3 | Merck Sharp & Dohme LLC MRK | NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemora | Carcinoma, Non-Small-Cell Lung | completed | 610 |
| 2026-06-09 | P3 | AstraZeneca AZN | NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small C | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | 454 |
| 2026-06-01 | P3 | AstraZeneca AZN | NCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | active not recruiting | 1246 |
| 2026-08-30 est. | P2 | TJ Biopharma Co., Ltd. | NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Loca | Non Small Cell Lung Cancer | active not recruiting | 150 |
| 2026-08 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06382116 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) | Non-small Cell Lung Cancer | active not recruiting | 432 |
| 2026-07-07 | P2 | AstraZeneca AZN | NCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | Lung Cancer | active not recruiting | 76 |
| 2026-05-31 | P2 | Akeso | NCT05932212 AK104 for Recurrent or Metastatic Vulvar Cancer | Vulvar Cancer | terminated | 20 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.